Cost-effectiveness and budget impact of Empirical XXXX therapy on unintentional falls in older adults in the UK.

@entity1 @entity204 @entity31864 @entity560
OBJECTIVES: To evaluate the health outcomes and economics associated with the current guidance relating to the prevention of falls in the elderly through @entity560 supplementation. SETTING: UK. @entity1 : UK population aged 60   years and above. INTERVENTIONS: A Markov health state transition model simulated @entity1 transitions between key fall-related outcomes using a 5-year horizon and annual cycles to assess the costs and benefits of empirical treatment with @entity31864 800   iu daily. PRIMARY AND SECONDARY OUTCOME MEASURES: Costs and health outcomes attributable to fall prevention following @entity560 supplementation. RESULTS: Our model shows that treating the UK population aged 60   years and above with 800   iu @entity31864 would, over a 5-year period: (1) prevent in excess of 430   000 minor falls; (2) avoid 190   000 major falls; (3) prevent 1579 acute @entity204 ; (4) avoid 84   000 @entity1 -years of long-term care and (5) prevent 8300 @entity204 associated with increased mortality in long-term care. The greatest gains are seen among those 75   years and older. Based on reduction in falls alone, the intervention in all adults aged 65+ is cost-saving and leads to increased quality adjusted life years. Treating all adults aged 60+ incurs an intervention cost of   2.70bn over 5   years, yet produces a -  3.12bn reduction in fall-related costs; a net saving of   420M. Increasing the lower bound age limit by 5-year increments increases budget impact to -  1.17bn, -  1.75bn, and -  2.06bn for adults 65+, 70+ and 75+, respectively. CONCLUSIONS: This study shows that treatment of the elderly UK population with @entity31864 800   iu daily would be associated with reductions in mortality and substantial cost-savings through fall prevention.
